CDBIO(SH:688739)2022-04-28 16:00Financial Performance - The company's revenue for Q1 2022 was ¥366,344,805.12, representing a decrease of 38.46% compared to the same period last year[5] - Net profit attributable to shareholders was ¥150,924,190.74, down 46.16% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥132,845,531.04, reflecting a decline of 53.21% compared to the previous year[5] - Basic earnings per share decreased by 52.00% to ¥0.36[5] - Total operating revenue for Q1 2022 was ¥366,344,805.12, a decrease of 38.5% compared to ¥595,277,477.18 in Q1 2021[38] - Net profit for Q1 2022 was ¥150,924,190.74, a decline of 46.3% from ¥280,299,418.02 in Q1 2021[40] - Basic and diluted earnings per share for Q1 2022 were both ¥0.36, compared to ¥0.75 in Q1 2021[41] - The net profit for Q1 2022 was ¥178,776,652.90, down 37.4% from ¥285,751,337.31 in Q1 2021[56] Research and Development - R&D investment totaled ¥69,235,416.34, a decrease of 16.42%, but accounted for 18.90% of revenue, an increase of 4.98 percentage points[7] - The company has initiated the construction of a biotechnology product R&D and production base with an estimated investment of RMB 1.4 billion to support the production needs of its HPV vaccine and other products[25] - The company is actively developing its ACYW135 meningococcal polysaccharide conjugate vaccine, with clinical trial applications accepted in March 2022[23] - Research and development expenses for Q1 2022 were ¥47,298,376.40, down 26.4% from ¥64,259,108.26 in Q1 2021[38] - Research and development expenses for Q1 2022 were ¥29,011,936.92, down 51.5% from ¥59,789,820.21 in Q1 2021[56] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,146,275.72, with an increase in cash received from sales compared to the previous year[13] - In Q1 2022, the company reported a net cash flow from operating activities of ¥38,146,275.72, a significant improvement compared to a net outflow of ¥27,054,458.17 in Q1 2021[43] - The company's cash inflow from operating activities totaled ¥320,536,823.33 in Q1 2022, an increase of 22.2% from ¥262,351,166.86 in Q1 2021[60] - Cash and cash equivalents at the end of Q1 2022 amounted to ¥2,270,823,998.45, down from ¥365,354,543.10 at the end of Q1 2021[45] - The net cash flow from investment activities was negative at ¥540,349,528.56, slightly better than the negative ¥593,850,177.17 recorded in Q1 2021[45] - Cash flow from financing activities resulted in a net outflow of -365,495.58, compared to -354,850.08 in the previous period[63] - The net increase in cash and cash equivalents for the period was -510,753,753.85, showing a decrease in liquidity[63] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,889,979,317.86, a slight increase of 0.99% from the end of the previous year[7] - The company's total assets increased to RMB 9,889,979,317.86 as of March 31, 2022, compared to RMB 9,792,731,456.06 as of December 31, 2021, reflecting a growth of about 1.0%[30] - The company's inventory as of March 31, 2022, was RMB 413,638,378.11, up from RMB 385,155,199.04 as of December 31, 2021, indicating an increase of approximately 7.0%[30] - Total liabilities decreased to ¥387,039,579.03 in the latest report from ¥440,715,907.97 in the previous period[33] - The company's total liabilities decreased to ¥249,198,833.13 in Q1 2022 from ¥421,212,228.65 in Q1 2021, representing a reduction of 40.8%[56] - The company's total equity increased to ¥9,602,030,411.99 in Q1 2022 from ¥9,423,253,759.09 in Q1 2021, reflecting a growth of 1.9%[56] Market Conditions - The decline in revenue was attributed to the impact of the Omicron variant and tightened domestic pandemic control measures, leading to reduced market demand[12] - The company faced increased competition in the human rabies vaccine market, contributing to the revenue decline[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,021[15] - Four of the top ten shareholders are involved in margin trading, holding a total of 73.43 million shares through credit securities accounts[20]